<DOC>
	<DOCNO>NCT02843191</DOCNO>
	<brief_summary>This trial ass efficacy feasibility consolidation chemotherapy neoadjuvant chemoradiotherapy locally advance mid low rectal cancer .</brief_summary>
	<brief_title>Consolidation Chemotherapy Locally Advanced Mid Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma mid low rectum 2 . Locally advanced rectal cancer confirm image ( i.e . Magnetic resonance image ) Clinical stage T13N1or2 MRI Clinical stage cT3N0 ( depth perirectal invasion tumor &gt; 5mm MRI ) Suspicious circumferential invasion MRI ( circumferential margin &lt; 1mm ) 3 . ECOG performance status 02 4 . ASA grade â‰¤ 3 5 . An informed consent sign patient 1 . Upper rectal cancer 2 . Clinical stage T1or2N0 MRI 3 . Clinical stage T4Nany MRI 4 . Clinical stage TanyNanyM1 image histology 5 . The patient receive chemotherapy radiotherapy past 6 month 6 . The patient receive therapy colorectal cancer another malignancy past 5 year 7 . The patient severe underlying disease poor condition receive chemotherapy radiotherapy 8 . Pregnant breastfeed woman 9 . The patient participate another clinical trial , receive drug trial 10 . Uncontrolled peripheral neuropathy ( grade 2 ) 11 . Any unhealed wound , fracture , peptic ulcer , intraabdominal abscess 12 . Active gastrointestinal bleeding 13 . Patients active infection , need antibiotic therapy , randomization period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rectal Cancer</keyword>
	<keyword>Consolidation Chemotherapy</keyword>
</DOC>